Furosemide
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pre-Eclampsia
Conditions
Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Trial Timeline
Jan 4, 2021 → Apr 29, 2022
NCT ID
NCT04615624About Furosemide
Furosemide is a phase 3 stage product being developed by Pacific Biosciences for Pre-Eclampsia. The current trial status is completed. This product is registered under clinical trial identifier NCT04615624. Target conditions include Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications.
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04615624 | Phase 3 | Completed |
Competing Products
3 competing products in Pre-Eclampsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + RLX030 | Novartis | Phase 2 | 27 |
| recombinant human relaxin | Novartis | Phase 1 | 33 |
| Sildenafil citrate | Pfizer | Phase 2 | 27 |